Hollis-Eden Pharmaceuticals About
Hollis-Eden Hollis-Eden is focused on a class of hormones
and analogs of hormones found in the body that it believes are important components
of the body's regulatory system. These compounds appear to reduce
inflammation in a broad–spectrum fashion while also improving a number of
components of the immune system in conditions of immune suppression. . Hollis-Eden currently has three drug
candidates in advanced development: HE2100 NEUMUNE is being co-developed
with the U.S. Department of Defense for use in protecting the body's bone marrow
from acute radiation syndrome. The compound is being developed pursuant to
a new rule enacted by the U.S. Food and Drug Administration (FDA) under which
approval may be granted on the basis of demonstrating efficacy in animals and
safety in humans. PHOSPHONOL™ , a non-IRH compound, has the potential
to protect against DNA mutations
(mutagenesis) that are believed to be a primary cause of the harmful long-term
effects of radiation injury associated with an increased risk of a variety
of cancers. With PHOSPHONOL and NEUMUNE™, Hollis-Eden could offer
products to treat both the short and long-term effects of radiation injury.
(HE2000) IMMUNITIN Has shown activity in malaria
and HIV. Given its anti-inflammatory
and anti-infective activities in clinical and preclinical studies, IMMUNITIN has
been selected by the Cystic Fibrosis Foundation for a collabortive research study.
In addition, the U.S. military is screening IMMUNITIN and other IRHs as countermeasures
against a number of pathogens that could be used as biowarfare agents.
More
on Hollis-Eden Key
Statistics for Hollis-Eden
Basic
Chart for Hollis-Eden